

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



EVEREST MEDICINES

云 頂 新 耀

Everest Medicines Limited

雲頂新耀有限公司

(incorporated in the Cayman Islands with limited liability)

(Stock Code: 1952)

**VOLUNTARY ANNOUNCEMENT
AGREEMENT WITH DIMERIX TO DEVELOP AND
COMMERCIALIZE DMX-200 IN GREATER CHINA,
SOUTH KOREA AND SOUTHEAST ASIA**

This announcement is made by Everest Medicines Limited (the “**Company**”) on a voluntary basis.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that on 16 June 2026, the Company entered into an agreement (the “**Agreement**”) with Dimerix Limited (“**Dimerix**”), a company listed on Australian Stock Exchange under the symbol “DXB”, pursuant to which Dimerix irrevocably granted to the Company an exclusive license to develop and commercialize DMX-200, a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of focal segmental glomerulosclerosis (“**FSGS**”), in Greater China, South Korea and certain Southeast Asian countries. DMX-200 has received orphan drug designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

Under the exclusive license, the Company’s payment obligations include: (i) an upfront payment of US\$10 million; and (ii) potential development and regulatory milestone payments of up to US\$30 million; (iii) potential sales milestone payments of up to US\$300 million; and (iv) potential tiered royalties between 10% to 15% based on future annual net sales.

This transaction is expected to further strengthen the Company’s nephrology product portfolio and pipeline synergy, reinforce the Company’s strategic position in kidney and autoimmune diseases.

As the highest applicable ratio in respect of the transaction contemplated under the Agreement is less than 5%, such transaction is exempt from the reporting, announcement and shareholders' approval requirements under Chapter 14 of the Rules Governing the Listing of Securities on the Stock Exchange of Hong Kong Limited.

ABOUT DMX-200

DMX-200 is a small molecule inhibitor of the chemokine receptor 2 (CCR2) under development in a pivotal, Phase 3 study, ACTION3, for the treatment of FSGS. DMX-200 has received orphan drug designations from the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).

ABOUT DIMERIX

Dimerix (ASX: DXB) is a clinical-stage biopharmaceutical company working to improve the lives of patients with inflammatory diseases, including kidney diseases. Dimerix is currently focused on developing its proprietary Phase 3 product candidate DMX-200, for Focal Segmental Glomerulosclerosis (FSGS) kidney disease. DMX-200 was identified using Dimerix' proprietary assay, Receptor Heteromer Investigation Technology (Receptor-HIT), which is a scalable and globally applicable technology platform, enabling the understanding of receptor interactions to rapidly screen and identify new drug opportunities. For more information, please visit the Dimerix's website at www.dimerix.com.

By order of the Board
Everest Medicines Limited
Yifang Wu
Chairman and Executive Director

Hong Kong, 16 June 2026

As at the date of this announcement, the Board comprises Mr. Yifang Wu as Chairman and Executive Director, Mr. Yongqing Luo and Mr. Ian Ying Woo as Executive Directors, Mr. Wei Fu, Mr. William Ki Chul Cho and Mr. Xin Sun as Non-executive Directors, and Ms. Hoi Yam Chui, Mr. Yifan Li and Mr. Shidong Jiang as Independent Non-executive Directors.